Australia-based biotechnology firm CSL announced on Monday, Oct. 26, 2026, that interim chief executive Gordon Naylor will become the company’s chair next year. Naylor will succeed Brian McNamee, who is scheduled to retire from the board on March 31, 2027.
The leadership change follows the Oct. 21 appointment of Deborah Waterhouse, a former GSK executive, as CSL's first female CEO. Naylor has served as interim CEO and managing director since February 2026, taking over after former CEO Paul McKenzie departed the company amid investor concerns over falling shares.
CSL reported that the board was unanimous in its decision to appoint Naylor to the chair position. The transition occurs as the company manages a period of restructuring, including a plan to cut 3,000 jobs. Following the announcement on Monday, CSL shares closed 0.8% lower at A$195.14, while the broader healthcare sub-index fell 0.5%.
For the company's shareholders, the transition represents an attempt to stabilize governance after the departure of the previous CEO in February. The market value of the company has been impacted by recent selloffs, and Jocum suggests that Naylor’s knowledge of the company’s internal operations is intended to assist the incoming CEO, Deborah Waterhouse, in managing the firm's current challenges.
The transition process will continue through the first quarter of 2027. Brian McNamee, who served as CEO and managing director from 1990 to 2013 before becoming chair, will conclude more than eight years in his current role when he retires on March 31, 2027. Gordon Naylor is scheduled to formally assume the chair position on that same date. No further executive changes or specific deadlines for the 3,000 job cuts were detailed in the company's recent announcements.